Journey’s end: the quest for BRCA-like hereditary breast cancer genes is nearly over     W D Foulkes; P Polak     Identifying markers of immune response in ovarian cancer: does PD-L1 expression meet the mark?     S L Gaillard; R L Coleman     Hyperprogression during immunotherapy: do we really want to know?     S Champiat; B Besse; A Marabelle     Circulating tumor cells are prognostic in SCLC, but still lack clinical application     M Tamminga; H J M Groen     Early-phase clinical drug development of novel agents: a changing paradigm     M de Miguel; E Calvo     Rare cancers: from centralized referral to networking     P G Casali     Anti-PD1 treatment of advanced melanoma: development of criteria for a safe stop     P Lorigan; A M M Eggermont     Efficacy of lung cancer screening appears to increase with prolonged intervention: results from the MILD trial and a meta-analysis     M Rota; M Pizzato; C La Vecchia; P Boffetta

Reviews       Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?     A Matikas; T Foukakis; S Swain; J Bergh     Targeting the PI3-kinase pathway in triple-negative breast cancer     J Pascual; N C Turner     Methods for measuring financial toxicity after cancer diagnosis and treatment: a systematic review and its implications     J Witte ; K Mehlis; B Surmann; R Lingnau; O Damm ...

Original articles         Breast tumors       Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers     K Nones; J Johnson; F Newell; A M Patch; H Thorne ...       Gynecological tumors       Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study     U A Matulonis; R Shapira-Frommer; A D Santin ; A S Lisyanskaya; S Pignata ...       Gastrointestinal tumors     Editor's Choice   Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy     J Hamfjord; T K Guren ; O Dajani; J S Johansen; B Glimelius ...     Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer     A B Schrock; C Ouyang; J Sandhu; E Sokol ; D Jin ...       Thoracic tumors       Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer     C G Kim; K H Kim; K -H Pyo; C -F Xin ; M H Hong ...     Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial     R Y Tay ; F Fernández-Gutiérrez; V Foy; K Burns; J Pierce ...   Editor's Choice   Crizotinib in ROS1 -rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001     A T Shaw ; G J Riely; Y -J Bang; D -W Kim; D R Camidge ...     A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer     R J Kelly; F A Shepherd; A Krivoshik; F Jie ; L Horn       Early drug development       Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors     M D Hellmann; T -W Kim; C B Lee; B -C Goh ; W H Miller, Jr. ...       Sarcoma     Editor's Choice   Surgery in reference centers improves survival of sarcoma patients: a nationwide study     J -Y Blay; C Honoré ; E Stoeckle; P Meeus; M Jafari ...       Melanoma     Editor's Choice   Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma     Y J L Jansen; E A Rozeman ; R Mason; S M Goldinger; M H Geukes Foppen ...       Cancer prevention     Editor's Choice   Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy     U Pastorino ; M Silva; S Sestini; F Sabia; M Boeri ...

Letters to the editor       Interactions between direct anticoagulants and chemotherapy     M Sorigue; E Sarrate; M D Miljkovic     RASA1 loss in a BRAF-mutated Langerhans cell sarcoma: a mechanism of resistance to BRAF inhibitor     F Jouenne; C Reger de Moura; G Lorillon; V Meignin ; N Dumaz ...     Immunotherapy in organ-transplanted cancer patients: efficacy and risk of organ rejection     J Ros; I Matos; J Martin-Liberal

Corrigenda       Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors     C Serrano; J Cortés; L De Mattos-Arruda; M Bellet; P Gómez ...     Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis     J Cortes; V Calvo; N Ramírez-Merino; J O'Shaughnessy ; A Brufsky ...     PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab     S Loibl; I Majewski; V Guarneri ; V Nekljudova; E Holmes ...     De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017     G Curigliano; H J Burstein; E P. Winer; M Gnant; P Dubsky ...